arXiv:2608. 12219v1 Announce Type: new Abstract: Treating patients with combinations of drugs reduces the risk of resistance to any individual drug.
By Antoine de Mathelin, Christopher Tosh, Wesley Tansey
The paper introduces a framework to predict whether a compound’s potency can be quantified in dose‑response profiling, treating quantifiability as a separate triage goal from biological activity. It shows that features from low‑cost primary screens, rather than molecular structure, strongly predict quantifiability, and that this prediction holds across new chemical scaffolds and assay families. The authors argue that incorporating quantifiability predictions can better allocate expensive dose‑response resources.
By Sean Lim
TopU-LBVS is a new multi‑target benchmark for ligand‑based virtual screening that addresses shortcomings of existing datasets by using hard‑negative decoys and a fixed 1:40 active‑to‑decoy ratio. It covers 93 protein targets across seven classes, provides three evaluation protocols (full, low‑data, and mini), and includes curated ChEMBL‑35 bioactivity data with property‑matched, structurally similar decoys. The benchmark demonstrates that performance drops sharply when moving from random‑decoy to hard‑negative evaluation, and it releases data, splits, code, and baseline implementations for reproducible comparison.
By Surbhi Kumar, Yuhe Zhou, Varun Shiralkar, Niu Huang, Baris Coskunuzer
The study evaluates the use of default decision thresholds (t=0.50) in multi‑label enzyme commission (EC) number prediction across 14,096 compounds and six EC classes. It finds a high mean accuracy of 77.16% but low macro F1 (0.3976) and macro recall (0.3872), indicating severe class‑imbalance issues: majority classes are over‑predicted while minority classes, especially EC6, have zero recall despite reasonable ROC‑AUC. The authors recommend target‑specific threshold tuning and conformal calibration as post‑processing safeguards to expose and correct these hidden errors.
By Bilal Ahmad, Rajed Mehmood
TopU-LBVS is a new multi‑target benchmark for ligand‑based virtual screening that addresses shortcomings of previous datasets by using hard‑negative decoys and a fixed 1:40 active‑to‑decoy ratio. It covers 93 protein targets across seven classes, provides three evaluation protocols (full, low‑data, and mini), and includes curated ChEMBL‑35 bioactivity data with property‑matched, structurally similar decoys to reduce shortcut learning. The benchmark comes with released data, fixed splits, evaluation code, and baseline implementations for reproducible comparison of LBVS and molecular representation methods.
arXiv:2604. 26498v3 Announce Type: replace Abstract: The rapid growth of molecular foundation models and large language models (LLMs) has encouraged a scale centred view of AI in drug discovery, in which larger pretrained models are expected to supersede compact cheminformatics models.
By Jinjiang Guo, Sheng Ding